MICOT PHARMA-B (02335.HK): To Be Included as Hang Seng Composite Index Constituent with Effect from 7 September

NewTimeSpace News: On 24 August 2026, Shaanxi Micot Pharmaceutical Technology Co., Ltd. (stock code: 02335.HK) issued a voluntary announcement, stating that according to the results of the quarterly index review of the Hang Seng Index Series for the period ended 30 June 2026 announced by Hang Seng Indexes Company Limited on 21 August 2026, the Company has been selected for inclusion as a constituent of the Hang Seng Composite Index (HSCI), with effect from 7 September 2026.

According to the announcement, following its inclusion in the HSCI, the Company's H shares are expected to become eligible for inclusion in the Stock Connect schemes (Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect), which serve as channels for investors in the Hong Kong and Mainland China capital markets to trade and invest in stocks. The board believes that the inclusion reflects the capital market's recognition of the Company's value and growth potential, which will help broaden the Company's shareholder base and enhance the trading liquidity of its H shares.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.